Arlanda

Arland Biopharma is a French biotechnology company focused on developing next-generation cancer immunotherapies that target the tumor microenvironment. The company utilizes its proprietary Arland platform to design innovative therapeutic antibodies and proteins aimed at overcoming resistance to current treatments. Its lead programs focus on neutralizing key immunosuppressive factors such as Transforming growth factor beta (TGF-beta) and Vascular endothelial growth factor (VEGF) to restore effective anti-tumor immune responses. By specifically modulating the local tumor environment, Arland Biopharma seeks to improve outcomes for patients with hard-to-treat solid tumors. The company is currently advancing its pipeline through pre-clinical development with the goal of entering clinical trials.